HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) and maintained an $18 price target.
June 21, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Fennec Pharmaceuticals and maintained an $18 price target.
The reiteration of a Buy rating and maintenance of an $18 price target by HC Wainwright & Co. analyst Raghuram Selvaraju is a positive signal for Fennec Pharmaceuticals. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100